ATE297394T1 - Jun kinase inhibitoren - Google Patents

Jun kinase inhibitoren

Info

Publication number
ATE297394T1
ATE297394T1 AT02714341T AT02714341T ATE297394T1 AT E297394 T1 ATE297394 T1 AT E297394T1 AT 02714341 T AT02714341 T AT 02714341T AT 02714341 T AT02714341 T AT 02714341T AT E297394 T1 ATE297394 T1 AT E297394T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
jun kinase
jun
present
compounds
Prior art date
Application number
AT02714341T
Other languages
English (en)
Inventor
Piotr Graczyk
Hirotoshi Numata
Afzal Khan
Vanessa Palmer
D Peter Medland
Hitoshi Oinuma
Gurpreet Bhatia
St Gower
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE297394T1 publication Critical patent/ATE297394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
AT02714341T 2001-04-06 2002-04-04 Jun kinase inhibitoren ATE297394T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0108770.9A GB0108770D0 (en) 2001-04-06 2001-04-06 Inhibitors
PCT/GB2002/001598 WO2002081475A1 (en) 2001-04-06 2002-04-04 Jun kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE297394T1 true ATE297394T1 (de) 2005-06-15

Family

ID=9912446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714341T ATE297394T1 (de) 2001-04-06 2002-04-04 Jun kinase inhibitoren

Country Status (7)

Country Link
US (1) US7314940B2 (de)
EP (1) EP1373269B1 (de)
JP (1) JP2004531519A (de)
AT (1) ATE297394T1 (de)
DE (1) DE60204553T2 (de)
GB (1) GB0108770D0 (de)
WO (1) WO2002081475A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
EP2324834B1 (de) * 2001-12-06 2019-05-08 Fibrogen, Inc. Verfahren zur Steigerung des endogenen Erythropoietins
EP1484320A1 (de) * 2002-02-13 2004-12-08 Takeda Chemical Industries, Ltd. Jnk-inhibitor
JP2005534618A (ja) * 2002-03-28 2005-11-17 エーザイ株式会社 神経変性疾患用の、ｃ−ｊｕｎｎ−末端キナーゼ阻害剤としての７−アザインドール
WO2003082869A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
JP2005538975A (ja) * 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
WO2004026406A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP1628975A2 (de) 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitoren
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
KR101128065B1 (ko) * 2004-05-26 2012-04-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
AU2005297966B2 (en) * 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
DE102005016547A1 (de) 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP1871770A1 (de) * 2005-04-22 2008-01-02 Kalypsys, Inc. Orthoterphenylhemmer der p38-kinase und verfahren zur behandlung von entzündungserkrankungen
GB0516156D0 (en) * 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
WO2007058304A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド化合物の塩またはそれらの溶媒和物
WO2007058305A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド誘導体の製造方法
NZ568050A (en) * 2005-11-24 2010-09-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EP2019094A4 (de) * 2006-05-19 2011-01-05 Eisai R&D Man Co Ltd Zimtsäureamidderivat vom heterocyclischen typ
EP2019093A4 (de) * 2006-05-19 2011-02-23 Eisai R&D Man Co Ltd Zimtsäureamidderivat vom harnstofftyp
SA07280403B1 (ar) * 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
DE102007009810A1 (de) * 2007-02-28 2008-09-04 Man Roland Druckmaschinen Ag Übertragungsform für einen Übertragungszylinder einer Druckmaschine
JPWO2008140111A1 (ja) * 2007-05-16 2010-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド誘導体のワンポット製造方法
EP3184527B1 (de) * 2007-06-22 2020-01-29 Eli Lilly and Company 2,6-dioxo,-2,3-dihydro-1h-purin-verbindungen zur behandlung von erkrankungen im zusammenhang mit der aktivierung des trpa1 kanals
MX2010002098A (es) 2007-08-31 2010-03-30 Eisai R&D Man Co Ltd Compuesto policiclico.
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CA2712095A1 (en) * 2008-01-28 2009-08-06 Eisai R&D Management Co., Ltd. Crystalline cinnamide compounds or salts thereof
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
EP2300466B1 (de) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Imidazopyridin- und imidazopyrazinverbindungen als kinasehemmer
EP2493876B1 (de) * 2009-10-28 2014-02-12 Pfizer Inc Imidazolderivate als casein-kinasehemmer
CN103764655B (zh) * 2011-07-13 2017-04-12 Sk化学公司 作为alk5和／或alk4抑制剂的经2‑吡啶基取代的咪唑
JP2015006993A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 イミダゾロン誘導体
GB201321743D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3413882A4 (de) * 2016-02-11 2019-10-09 Mordechai Chevion Verfahren und pharmazeutische zusammensetzung zur behandlung von neurodegeneration
KR102510351B1 (ko) * 2020-02-28 2023-03-17 한양대학교 에리카산학협력단 단백질 인산화 효소 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719218A (en) * 1985-12-12 1988-01-12 Smithkline Beckman Corporation Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
GB9026926D0 (en) * 1990-12-12 1991-01-30 Smith Kline French Lab Novel process
EP0563286A4 (en) * 1990-12-13 1995-01-11 Smithkline Beecham Corp Novel csaids
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
ES2301255T3 (es) * 1998-12-17 2008-06-16 F. Hoffmann-La Roche Ag 4,5-pirazinaxindoles como inhibidores de proteinoquinasas.
AU760039B2 (en) 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
KR100835700B1 (ko) * 1999-08-19 2008-06-09 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를 함유하는 조성물
DE60006634T2 (de) 1999-12-07 2004-04-15 Fuji Photo Film Co., Ltd., Minami-Ashigara Fluoreszente materialen
CA2699568C (en) 1999-12-24 2013-03-12 Aventis Pharma Limited Azaindoles
ATE387199T1 (de) 2000-01-06 2008-03-15 Merck Frosst Canada Ltd Neue substanzen und verbindungen als protease- inhibitoren
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2003082869A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases

Also Published As

Publication number Publication date
US20040235864A1 (en) 2004-11-25
EP1373269A1 (de) 2004-01-02
EP1373269B1 (de) 2005-06-08
WO2002081475A1 (en) 2002-10-17
JP2004531519A (ja) 2004-10-14
US7314940B2 (en) 2008-01-01
DE60204553D1 (de) 2005-07-14
GB0108770D0 (en) 2001-05-30
DE60204553T2 (de) 2006-03-16

Similar Documents

Publication Publication Date Title
DE60204553D1 (de) Jun kinase inhibitoren
WO2004078756A3 (en) Jnk inhibitors
ATE486870T1 (de) Jnk inhibitoren
GB0405055D0 (en) JNK inhibitors
DE60316542D1 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
WO2004101565A3 (en) Jnk inhibitors
DE60331219D1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
GEP20125368B (en) Kinase inhibitors
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
DK1660507T3 (da) Proteasominibitorer og metoder til anvendelse heraf
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
EP2134346A4 (de) Hemmer von janus-kinasen und/oder 3-phosphoinositid-abhängiger protein-kinase 1
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
TW200505904A (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
ATE424208T1 (de) Proteinkinaseinhibitoren
TW200740808A (en) Inhibiteurs de proteines kinases
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
IL162820A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
BRPI0416777A (pt) composto de piridinil metanona substituìdos por amino úteis no tratamento de disturbios da quinase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties